The Skin and Soft Tissue Infection Hospital Registry (SSTIR), the first national registry of complicated skin and soft tissue infections (cSSTIs), has debuted under the sponsorship of Ortho-McNeil, a division of Ortho-McNeil-Janssen Pharmaceuticals Inc.
The organizers of the SSTIR plan to enroll more than 1,200 hospitalized patients by the end of this year. The purpose of the new United States-based registry is to better understand treatment patterns and provide data to help improve patient outcomes, according to spokespersons at the pharma company.
More than 50 United States-based hospitals will participate in this prospective, multicenter registry, which will comprehensively characterize the four major types of cSSTIs: diabetic foot infections, surgical site infections, deep soft tissue abscesses, and cellulitis (an infection of tissue under the skin).
In addition, the study will observe patient management in the hospital setting, including selection and timing of antibiotic treatment, changes in treatment regimen, outcomes, and economic impact.